Phosphorylation of the actin-associated protein caldesmon (CaD) by extracellular signalregulated kinases (ERK1/2) is purported to participate in force maintenance by vascular smooth muscle. We examined the interrelationship among ERK1/2 activity, phosphorylation of the high molecular weight isoform of CaD (h-CaD) and the 20-kDa myosin light chain (LC 20 ), and isometric force in strips of porcine carotid artery stimulated with endothelin-1 (50 nM). After an initial delay, ERK1/2 activity increased in parallel with ET-1-mediated force; h-CaD phosphorylation increased modestly. PD 098059 (50 µM), an ERK1/2 kinase inhibitor, significantly reduced basal ERK1/2 activity within 1 hour, but only partially attenuated h-CaD phosphorylation at three hours. The mechanisms underlying the temporal dissociation of ERK1/2 activity from h-CaD phosphorylation are unknown, but include the possibility that a kinase other than ERK1/2 phosphorylates h-CaD or, more likely, that phosphate turnover in hCaD is very slow. PD 098059 partially inhibited the development of ET-1-stimulated force only in Ca 2+ -replete PSS, primarily by reducing LC 20 phosphorylation, yet had no effect on myosin light chain kinase in vitro. These inhibitory effects were most evident during the early phase of force production. The inhibitory effect of PD 098059 on force could not be correlated with a corresponding effect on ERK1/2-mediated h-CaD phosphorylation since force in arterial strips stimulated with ET-1 in the absence or presence of PD 098059 tended to approximate each other over time despite significant differences in the level of h-CaD phosphorylation. Force and LC 20 phosphorylation in response to KCl depolarization was unaffected by PD 098059. These results show that ERK1/2 may regulate force in arterial smooth muscle, but suggest that the mechanism for this effect is by inhibiting LC 20 phosphorylation.……..
INTRODUCTION
In vascular smooth muscle (VSM), it is well established that isometric force production and/or muscle shortening is regulated by calcium (Ca 2+ proposed that force is maintained by an additional mechanism(s) independent of LC 20
phosphorylation. Attention has focused on the role of actin-associated proteins, in particular, caldesmon (CaD), in the regulation of VSM force. CaD is an elongated, protein possessing binding sites for actin, Ca 2+ /calmodulin, tropomyosin, and myosin. Alternate splicing of the CaD gene yields two isoforms: a 93-kDa protein, h-CaD, which is specific to contractile smooth muscle, and a 60-kDa protein, l-CaD, which is expressed ubiquitously (see 25 for review).
To date, there exists some evidence supporting a role for h-CaD in the regulation of VSM force.
Biochemical characterization of h-CaD demonstrated that h-CaD inhibits the actinactivated myosin adenosinetriphosphatase (ATPase) activity in reconstituted systems of purified contractile proteins (23). Katsuyama et al. (17) found that a peptide fragment of h-CaD which has no effect on myosin ATPase produced a concentration-dependent increase in force at a fixed Ca 2+ concentration in permeabilized VSM cells. Using anti-sense nucleotides to produce porcine carotid smooth muscle tissue deficient in h-CaD, Earley et al. (8) showed that unstimulated h-CaD-deficient arterial strips redeveloped force following a stretch-release protocol, whereas h-CaD-containing strips did not. Separately, these authors concluded h-CaD exerts an inhibitory effect on VSM in the resting state.
Our laboratory has previously shown phosphorylation of h-CaD parallels isometric force production (3), lending credence to the notion that h-CaD phosphorylation may reverse, or at least modulate the effects of h-CaD in vivo.
Although phosphorylation of h-CaD by such kinases as protein kinase C (27) and Ca 2+ /calmodulin-dependent kinase II (23,26) can reverse its inhibitory effect on myosin ATPase, we have since identified the 44-and 42-kDa isoforms of the extracellular signal-regulated kinase (ERK1/2) as physiologically relevant "CaD kinases" in intact VSM (1, 2, 4) . It is unknown, however, whether h-CaD phosphorylation at ERK1/2-specific sites reverses the ability of h-CaD to inhibit actin-activated myosin ATPase. Watts and colleagues (10, 28, 29) have provided evidence of a functional relationship between ERK1/2 and isometric force in VSM, demonstrating that PD 098059, a novel inhibitor of ERK activation (7), attenuated not only serotonin-induced contraction of rat aorta, but also ERK1/2 activity. On the other hand, studies aimed at determining the role of ERK-dependent phosphorylation of hCaD in the regulation of smooth muscle force have yielded conflicting results. Whereas recombinant ERK potentiated the Ca 2+ -mediated contraction of skinned tracheal smooth muscle (12) , it had no effect on the Ca 2+ -sensitivity of skinned preparations of rabbit portal vein or femoral artery (24).
Since ERK1/2 are physiologically relevant "CaD kinases" that may be involved in contractile regulation, the aim of this study therefore was to characterize the causal relationship among ERK1/2 activation, h-CaD and LC 20 phosphorylation, and force maintenance in intact arterial strips. To this end, we determined: 1) the temporal relationship among these parameters in porcine carotid arteries stimulated with ET-1, and 2) the effect of PD 098059, an inhibitor of ERK1/2, LC 20 and h-CaD phosphorylation, and isometric force. We report that although phosphorylation of ERK1/2 and h-CaD are temporally related to the sustained level of ET-1-stimulated force, attenuation of force caused by ERK1/2 inhibition appears to be mediated principally by a reduction in LC 20 phosphorylation.
METHODS

Materials
Unless specified otherwise, reagents were purchased from Sigma Chemical Co. (St. Louis, MO). Purified LC 20 used to determine ATP specific activity for measurement of absolute ERK1/2 enzymatic activity using an in vitro kinase assay and for myosin light chain phosphorylation in vitro, was generously given to us by Dr. Renne Lu (Boston Biomedical
Research Institute). Calmodulin (CaM) was purified from bovine testicles according to Klee (18) . MLCK was purified from chicken gizzards according to Hathaway et al. (15) . I-protein A (secondary antibody). As previously described, radioactive bands were cut out, and counted using a Beckman 5500 gamma counter.
In vitro myosin light chain phosphorylation 
RESULTS
Time course of ERK1/2 activity and CaD phosphorylation
Initial experiments were aimed at examining the time courses of ERK1/2 activation and of hCaD phosphorylation in response to ET-1 (50 nM). Since basal ERK1/2 activity progressively declines after applying a preload to arterial strips mounted for measuring isometric force (11), the duration of each experiment was held constant at four hours. ET-1-(50 nM ) stimulated force rose to 82±6% of the KCl response by 15 minutes, and decreased only slightly to 72±3% over the next 45 minutes (Fig. 1 ). ET-1 also produced a time-dependent increase in ERK1/2 activity, the onset of which was delayed relative to the rise in force. ET-1-mediated ERK1/2 activity peaked at 15 minutes, reaching nearly twice that of control (46±6 vs. 89±7 pmol·min Accompanying changes in the level of h-CaD phosphorylation were measured separately by
Western blot analysis using a polyclonal antibody generated against the phosphopeptide, 
Effects of PD 098059
We first examined the effect of 50 µM PD 098059 on basal ERK1/2 activity and CaD phosphorylation in arterial segments incubated with PD 098059 for 1, 2, or 3 hours. To facilitate the correlation of ERK1/2 activity and CaD phosphorylation, these experiments were performed using an anti-phosphoERK1/2 antibody to assess relative changes in ERK1/2 activity, and accompanying changes in the relative levels of h-CaD phosphorylation were determined using the anti-phosphoCaD antibody described above. To explore the possible regulation of ERK1/2 activity by Ca 2+ , experiments were performed in Ca 2+ -free and Ca 2+ -replete PSS. Arterial strips were maintained in Ca 2+ -free PSS one hour prior to and during administration of PD 098059.
Due to the constraints imposed by the time-dependent decrease in basal ERK1/2 activity following the mounting and application of preload to the arterial strips (11) We then tested whether pre-incubation (1 hour) with PD 098059 could impact on ET-1-stimulated isometric force in either Ca 2+ -free and Ca 2+ -replete PSS, given the observed inhibitory effect of PD 098059 on basal ERK1/2 activity. Treatment with 50 µM PD 098059 had no effect on either the rate of force development (data not shown) or the F max achieved in Ca 2+ -free PSS (Fig. 3) ; prolonged incubation up to 3 hours similarly had no effect on ET-1-stimulated responses (data not shown). On the other hand, F max was significantly reduced in Ca 2+ -replete PSS (Fig. 3) . Moreover, the temporal characteristics of ET-1-stimulated force were dramatically altered by PD 098059. Effects of pre-incubation with PD 098059 are summarized in Figure 4 .
In control strips stimulated with ET-1, isometric force characteristically rose at a consistent rate over the first 15 minutes, after which time it began to level off. Isometric force was maintained over the next 15 minutes, where F max was equal to 85±4% of the KCl response (@ t=25 minutes) . As previously observed (see Fig. 1 ), isometric force only partially declined over the ensuing 30 minutes to 77±3% of the KCl response. Conversely, in arterial strips pretreated with PD 098059, the rate of force development paralleled that for control tissues only over the first 2.5 minutes, after which time, there was a divergence in the rate of force production.
Specifically, force increased more slowly than in control tissues such that peak levels were significantly less (65±4% of KCl response; p<0.01), and were attained at a later time point (i.e.
@ 45 minutes or later); force remained invariant up to 60 minutes (Fig. 4A) . By one hour, however, isometric force tended to converge toward, but did not yet reach a common level due to the slow decrease in force in control tissues. and 30 minutes after the addition of ET-1 were significantly lower in arterial strips which had been pretreated for 1 hour with PD 098059 (Fig. 4B) . To determine the relative specificity of PD 098059, we examined its effect on responses to KCl depolarization ( Fig. 5A and B) . Whereas PD 098059 did not affect the development of force following the addition of KCl (110 mM), it did cause a slight, though not statistically significant decrease in steady-state force (Fig. 5A ). As well, KCl-mediated LC 20 phosphorylation was unaffected by PD 098059 (Fig. 5B ). Finally, we tested whether the effect on ET-1-stimulated LC 20 phosphorylation caused by PD 098059 was due to a direct effect on myosin light chain kinase (MLCK) by measuring the activity of MLCK in vitro in the absence or presence of PD 098059. As shown in Fig. 6 , 50 or 100 µM PD 098059
had no direct effect on either the rate or extent of LC 20 phosphorylation by MLCK.
In a separate set of experiments, we also measured the effect of pretreatment with PD 098059 on ET-1-stimulated CaD phosphorylation by immunoblot analysis using the anti-pSer 789 antibody.
The effect of PD 09859 on ERK1/2 activity was verified by monitoring immunoreactivity with an anti-phosphoERK antibody (Fig. 7B) . Since no effect of PD 098059 on isometric force had previously been detected in Ca 2+ -free PSS, even after prolonged incubation for 3 hours (data not shown), experiments were only performed in Ca 2+ replete PSS. Arterial segments were stimulated with 50 nM ET-1 following pretreatment with either vehicle (0.5% DMSO) or 50 µM PD 098059, and frozen either after 15 or 60 minutes, the time points corresponding to the maximal increases in ERK1/2 activity and CaD phosphorylation, respectively. In vehicle control muscle strips, the level of h-CaD phosphorylation increased slightly 15 minutes after the addition of ET-1 (27±11%), but had more than doubled by 60 minutes (123±33%) (Fig. 7A) . As before, pretreatment with PD 098059 for 1 hour had no effect on basal h-CaD phosphorylation. Relative to the vehicle-treated controls, ET-1-stimulated hCaD phosphorylation rose slightly by 15 minutes (28±16%) in the presence of PD 098059, and did not increase further at 60 minutes (34±26%) (Fig. 7A) . Due to the large variability in these responses, these values did not reach statistical significance. Relative to the baseline level for PD 098059-treated tissues, ET-1 stimulation produced increases in h-CaD phosphorylation of 35% and 41% at 15 and 60 minutes, respectively.
DISCUSSION
Dissociation of force and CaD phosphorylation
To address the role of h-CaD phosphorylation by ERK in smooth muscle function, we examined the temporal relationships among isometric force, h-CaD phosphorylation at ERKmodulated sites, and ERK activity in carotid arteries. Specifically, we found that whereas there was a consistent near doubling of ET-1-stimulated ERK1/2 activity, the increase in ERKdependent h-CaD phosphorylation was much less. In a previous study (6), we found that the stoichiometry of phosphorylation at Ser Whereas force in vehicle-treated tissues declined slightly from a peak level over the time investigated, force in PD 098059-treated strips held constant after attaining a maximal level.
Moreover, although force in arterial strips from the two groups tended to approximate each other by 60 minutes, it was still significantly elevated in control tissues.
Conversely, the relative increases in ET-1-stimulated h-CaD phosphorylation after 15 minutes were similar in non-and PD 098059-treated arterial strips when normalized to their respective controls, whereas h-CaD phosphorylation was significantly reduced in PD 098059-treated strips at 60 minutes. Thus, at a time point where force tended to converge, we detected significant differences in the level of h-CaD phosphorylation. Since the early phase of force development in regulated primarily by LC 20 phosphorylation, our data are more consistent with a model in which early signaling events, e.g. MLCK activity and LC 20 phosphorylation, are modulated directly by ERK1/2 activity, or indirectly by the MEK inhibitor PD 098059. Previously, Gorenne et al. (14) reported that PD 098059 had no effect on either basal or stimulated LC 20
phosphorylation following the addition of either PDBu or histamine. The time points at which LC 20 phosphorylation measurements were made, however, was not specified. In our study, there was a significant attenuation of LC 20 phosphorylation at the time of peak ET-1-mediated force, but no difference 60 minutes after the addition of ET-1. Thus, depending on when LC 20 phosphorylation is measured, an effect of PD 098059 may or may not be detected.
Interaction between ERK1/2 and MLCK Similar to the findings of Watts and colleagues (10, 28, 29), we found that pretreating carotid arterial strips for one hour with the MEK inhibitor PD 098059 attenuated agonist-stimulated isometric force. In the present study, the decrease in the rate of force development caused by PD 098059 was associated with a reduction in LC 20 phosphorylation, an outcome that was not predicted by our original hypothesis. This inhibitory effect was detected in Ca 2+ -replete PSS, but not in Ca 2+ -free PSS, where the rise in force was not accompanied by an elevation in LC 20
phosphorylation. Not even with prolonged incubation (3 hours) was there a significant effect on ET-1-mediated force in Ca 2+ -free PSS. It is unlikely that one hour incubation in Ca 2+ -free PSS is sufficient to deplete all the intracellular Ca 2+ stores; however, ET-1 did produce a contraction in extracellular Ca 2+ -depleted muscles that occurred in the absence of measurable changes in LC 20 phosphorylation. Thus it follows that ET-1 may not evoke a significant change in intracellular calcium under these conditions, although local Ca 2+ responses in response to receptor activated pools or through other mechanisms (insufficient to yield measurable increases in LC 20 phosphorylation) can not be ruled out. In the latter scenario where there may be local increases in Ca 2+ , the lack of effect of PD 098059 on ET-1-stimulated force in Ca 2+ -free PSS argues against a role for ERK1/2 in modulating the release of Ca 2+ from intracellular pools.
Nevertheless, PD 098059 attenuated the rise in force only during the situation where force was associated with an increase in LC 20 phosphorylation.
We also addressed the possibility that the effect of PD 098059 on force may be non-specific.
In so doing, we found that PD 098059 had no effect on force development and LC 20 phosphorylation elicited by KCl depolarization, ruling out the possibility that MLCK was nonspecifically down regulated; there was, however, a small, yet insignificant attenuation of force at steady-state. These data also argue against an effect of ERK inhibition on calcium entry, although it is entirely possible that any effect is simply overcome by the degree of depolarization and ensuing Ca 2+ influx. Moreover, neither 50 nor 100 µM PD 098059 had a direct inhibitory effect on MLCK activity in vitro. These data suggest that LC 20 serves as a substrate within the signaling cascade downstream of ERK1/2, either directly or through the involvement of an intermediate kinase(s).
Direct evidence of a causal relationship between ERK and MLCK activity was provided by Klemke et al. (19) . These authors showed that purified, constitutively active ERK1/2 phosphorylated chicken gizzard MLCK and enhanced its phosphotransferase activity in vitro. 
